PT - JOURNAL ARTICLE AU - Chirag K. Kumar AU - Ruchita Balasubramanian AU - Stefano Ongarello AU - Sergio Carmona AU - Ramanan Laxminarayan TI - SARS-CoV-2 Testing Strategies for Outbreak Mitigation in Vaccinated Populations AID - 10.1101/2022.02.04.22270483 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.04.22270483 4099 - http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270483.short 4100 - http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270483.full AB - Although COVID-19 vaccines are globally available, waning immunity and emerging vaccine-evasive variants of concern have hindered the international response as COVID-19 cases continue to rise. Mitigating COVID-19 requires testing to identify and isolate infectious individuals. We developed a stochastic compartmentalized model to simulate SARS-CoV-2 spread in the United States and India using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) assays, rapid antigen tests, and vaccinations. We detail the optimal testing frequency and coverage in the US and India to mitigate an emerging outbreak even in a vaccinated population: overall, maximizing frequency is more important, but high coverage remains necessary when there is sustained transmission. We show that a resource-limited vaccination strategy still requires high-frequency testing and is 16.50% more effective in India than the United States. Tailoring testing strategies to transmission settings can help effectively reduce cases more than if a uniform approach is employed without regard to differences in location.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Foundation for Innovative New Diagnostics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only publically available datasets, either available through the U.S. Center for Disease Control or peer-reviewed studies. All data sources are detailed in the supplementary material: citations are included to the data sources and links to downloading the data online.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this paper is freely and publicly accessible through the US Center for Disease Control or peer-reviewed studies. The provided supplementary materials document details data sources and includes citations to all the relevant sources.